We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IVZ:NYSEInvesco Ltd Analysis

Data as of 2026-04-11 - not real-time

$23.58

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Invesco Ltd. (IVZ) trades at $23.58, roughly 19% below its DCF‑derived fair value of $26.97, and offers a 3.56% dividend yield with a 56% payout ratio. The forward P/E of 8.1 is less than half the asset‑management industry average of 17.1, reinforcing the stock’s undervalued label in recent analyst screens. Technicals are mixed: the 20‑day SMA sits just above price, the MACD histogram is positive indicating a slight bullish bias, while RSI at 46 suggests no immediate overbought pressure; support sits near $21.82 and resistance at $24.79. Volatility remains elevated at over 40% (30‑day) and beta is high at 1.67**, reflecting sensitivity to market swings. Recent news highlights include its inclusion in a “most undervalued financial stocks” list, praise for dividend attractiveness, the launch of the Invesco QQQ Equal Weight ETF, and a downgrade to Hold with a $21 target, while a competing BlackRock Nasdaq‑100 ETF filing adds short‑term competitive pressure. Despite these headwinds, the firm reported a modest 1.2% AUM growth and is expanding into private real estate, suggesting a resilient earnings outlook ahead of the Q1 2026 results release on April 28.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Upcoming Q1 earnings release (April 28) may clarify profitability trends
  • Recent downgrade to Hold and competitive pressure from BlackRock's Nasdaq‑100 ETF
  • Price near technical support with modest upside potential

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF upside of ~19% and analyst consensus Buy with median target $27
  • Attractive dividend yield and sustainable payout
  • Expansion into private real estate and new ETF offerings driving AUM growth

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistent cash flow generation and solid free cash flow
  • Low valuation multiples relative to industry peers
  • Diversified product suite and global investment platform supporting steady earnings

Key Metrics & Analysis

Financial Health

Revenue Growth6.20%
Profit Margin-4.42%
P/E Ratio8.1
ROE-1.22%
ROA2.60%
Debt/Equity17.16
P/B Ratio1.1
Op. Cash Flow$1.5B
Free Cash Flow$745.7M
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI46.1
Support$21.82
Resistance$24.79
MA 20$23.61
MA 50$25.02
MA 200$23.58
MACDBullish
VolumeIncreasing
Fear & Greed Index87.09

Valuation

Fair Value$26.97
Target Price$28.09
Upside/Downside19.13%
GradeUndervalued
TypeValue
Dividend Yield3.56%

Risk Assessment

Beta1.67
Volatility40.20%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.